Insulete Inc., a Madison start-up that is aiming to cure Type 1 diabetes with gene therapy, has raised $300,000 of equity funding from one investor, according to afiling with federal securities regulators.

This is the first time the 12-year-old company has raised outside funding, according to

Insulete was founded and is headed by Hans Solinger, a well-known transplant surgeon and University of Wisconsin-Madison researcher who has helped bring pharmaceutical drugs to market. Sollinger and Tausif Alam, Insulete’s chief financial officer, discovered and patented a DNA sequence that is glucose responsive and promotes the activation of the human insulin gene. Read the full Journal Sentinel story here.